Healthcare: Alkermes Super-Bad Day, and Illumina's Surprising M&A News

Industry Focus - A podcast by The Motley Fool

Categories:

Business

Why Alkermes once-promising depression drug failed to impress the FDA's advisory committee. Plus, how a $1.2 billion acquisition of Pacific Biosciences could move the needle at Illumina. Stocks: ALKS, ILMN, PACB